Personalized Cancer Vaccine Plus Immune Cell Therapy for Advanced Sarcoma
Part of Cancer clinical trials.
This study tests a personalized vaccine made from your tumor's unique mutations, combined with special immune cells grown from your blood, to treat advanced sarcoma (bone or soft tissue cancer) that did not respond to initial treatment. The goal is to help your immune system recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Advanced or unresectable sarcoma (bone or soft tissue cancer) that failed first-line treatment
- Never received a cancer vaccine or PD-1 antibody before
- Measurable tumors visible on imaging and physical exam
- Good overall health (ECOG score 0–1) with expected survival over 6 months
- Blood work and heart function within safe limits; no cancer drugs or radiation for 4 weeks before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines cryoablation (a freezing technique to destroy tumors) with camrelizumab (an immunotherapy drug that helps your immune system fight cancer) for patients with advanced soft tissue sarcoma that hasn't responded to standard treatments. The goal is to see if this combination works better than current options.
This trial tests a new combination therapy: an injected virus (OVV-01) alongside an immunotherapy drug (AK112) for people with advanced soft tissue sarcoma that hasn't responded to usual treatments. The aim is to see if this approach can help shrink tumors or slow their growth.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
This trial tests a personalized vaccine made from unique markers on your tumor cells (called neoantigens). The goal is to help your immune system fight the cancer more effectively. It is for people with advanced solid tumors who have not had gene therapy and are otherwise relatively healthy.
This trial tests a personalized mRNA vaccine (RH125) designed to train your immune system to attack your cancer. It is for people with advanced solid tumors that have not responded to standard treatments, and it aims to see if the vaccine is safe and helpful.
This trial tests a new treatment that uses your own immune cells, modified to attack sarcoma cancer cells. It may help people with advanced or recurrent sarcoma who have not responded to other treatments.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.